Stock futures are surging after the Fed signaled interest rate cuts may begin as early as July.US Marketsread more
A surface-to-air missile shot down a U.S. military drone over the Strait of Hormuz, a U.S. official said Thursday.World Politicsread more
President Donald Trump has publicly blamed the Federal Reserve's interest rates hikes for holding back U.S. economic growth.The Fedread more
Slack's public market debut on Thursday will generate billions for venture firm Accel and healthy returns for Andreessen Horowitz and Social CapitalTechnologyread more
China's President Xi Jinping arrived in Pyongyang on Thursday morning for a state visit to North Korea — the first by a Chinese state leader in 14 years. Experts say the move...Asia Politicsread more
Gold prices spiked in the afternoon of Asian trading hours on Thursday after a dovish U.S Federal Reserve opened the door to further rate cuts, and the 10-year Treasury yield...Metalsread more
In an area responsible for the shipment of one-third of the world's seaborne oil, just how high could military confrontation — or indeed, an outright war — send the price of...Oilread more
Waymo has signed a deal with Renault and Nissan to develop self-driving cars and trucks for use in France, Japan and possibly other countries in Asia, including China, the...Autosread more
Employer medical costs are projected to rise by 6% next year, after averaging about 5.5% annually over the last three years, according to PwC.Health and Scienceread more
Voice technologies have a long way to go before they can be reliably used for health and medical services, but Google is furthest along.Technologyread more
The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Canada's Valeant Pharmaceuticals reported a better-than-expected quarterly profit and said it expected to repay more than $5 billion in debt earlier than it had targeted, sending its shares up 10 percent.
Since taking the helm in April 2016, Joseph Papa has been trying to rebuild the company's business and regain investor confidence after a flurry of investigations into its accounting and pricing practices.
One of Papa's biggest challenges has been to cut the company's towering debt, which ballooned to nearly $30 billion following a spate of deal-making under former CEO Mike Pearson.
The company said on Tuesday it was continuing to reduce debt and resolve legacy issues, and that it expected to exceed its pledge to reduce $5 billion in debt earlier than February.
Valeant had long-term debt of about $28.5 billion as of June 30.
Last month, the drugmaker paid down $811 million of debt with proceeds from the sale of its cancer treatment unit Dendreon Pharmaceuticals, and agreed to sell its Obagi Medical Products business for $190 million. In June, Valeant agreed to sell its iNova Pharmaceuticals business for $930 million.
The maker of Bausch + Lomb contact lenses also lowered its revenue forecast for the year.
Valeant said it now expects revenue of $8.70 billion to $8.90 billion for the full year, compared with its previous forecast of $8.90 billion to $9.10 billion.
However, it maintained its 2017 forecast for adjusted earnings before interest, tax, depreciation and amortization.
Excluding items, the company earned $1.05 per share, ahead of the average analyst estimate of 94 cents, according to Thomson Reuters I/B/E/S. The beat was mainly due to strong sales of Valeant's irritable bowel syndrome drug Xifaxan.
Revenue of $2.23 billion was roughly in line with expectations.
On Monday, the FDA declined to approve Valeant's eye drop for the second time in a little over a year, raising concerns over Bausch + Lomb's manufacturing facility in Tampa, Florida.
U.S.-listed shares of the Laval, Quebec-based company were up about 10.3 percent at $16.96 in premarket trading on Tuesday.